Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica Sacro Cuore, Rome, Italy.
Int J Cardiol. 2024 Oct 15;413:132392. doi: 10.1016/j.ijcard.2024.132392. Epub 2024 Jul 25.
Patients experiencing non-ST segment elevation acute-coronary-syndromes (NSTE-ACS) often present with multivessel-coronary-artery-disease (MVD). An immediate complete multivessel revascularization (MVR) - within the index hospitalization - may be considered the default therapeutic strategy, although its risk-to-benefit profile has not been definitively established through dedicated clinical trials.
A systematic review and meta-analysis, adhering to MOOSE and PRISMA guidelines, was conducted to assess studies comparing immediate MVR versus a conservative culprit-only revascularization (COR) in NSTE-ACS with MVD. The main endpoints were all-cause death, major adverse cardiovascular events (MACE) and non-fatal myocardial infarction (MI). The incidence of any revascularization or further percutaneous-coronary-interventions (PCIs) were also collected. The primary analyses for the main endpoints were conducted on propensity-matched groups only.
A total of 22 studies (182,798 patients) were identified. 7 studies, encompassing 11,372 patients, were included in the primary analysis of propensity score-matched groups. Immediate MVR significantly increased (28%) survival (OR 0.72, 95% CI 0.58-0.90, P < 0.01) along with a 35% reduction in MACE (OR 0.65, 95% CI 0.47-0.88, P = 0.01) and a 60% decrease in MI (OR 0.40, 95% CI 0.25-0.63, P < 0.01) during a mean 3-years follow-up compared to the propensity score-matched COR group. Results were consistent in the unmatched analyses.
This meta-analysis supports an immediate MVR for improving clinical outcomes in patients with NSTE-ACS and MVD as compared to a conservative immediate COR. These data prompt further evaluations regarding optimal strategies in the pursuit of MVR, including patient selection, revascularization modality, and assessment methods of revascularization completeness.
患有非 ST 段抬高型急性冠状动脉综合征(NSTE-ACS)的患者常伴有多支血管冠状动脉疾病(MVD)。在指数住院期间立即进行完全多支血管血运重建(MVR)可能被视为默认的治疗策略,尽管其风险效益比尚未通过专门的临床试验得到明确确定。
按照 MOOSE 和 PRISMA 指南进行系统评价和荟萃分析,以评估比较立即进行 MVR 与保守的罪犯血管血运重建(COR)治疗伴有 MVD 的 NSTE-ACS 的研究。主要终点是全因死亡、主要心血管不良事件(MACE)和非致死性心肌梗死(MI)。还收集了任何血运重建或进一步经皮冠状动脉介入治疗(PCIs)的发生率。主要终点的主要分析仅在倾向匹配组上进行。
共确定了 22 项研究(182798 名患者)。纳入了 7 项研究(包括 11372 名患者),对倾向评分匹配组进行了主要分析。与倾向评分匹配的 COR 组相比,立即进行 MVR 可显著提高(28%)生存率(OR 0.72,95%CI 0.58-0.90,P<0.01),同时降低 MACE(OR 0.65,95%CI 0.47-0.88,P=0.01)和 MI(OR 0.40,95%CI 0.25-0.63,P<0.01)的发生率,平均随访 3 年。在未匹配的分析中结果一致。
与保守的立即 COR 相比,该荟萃分析支持对伴有 MVD 的 NSTE-ACS 患者立即进行 MVR,以改善临床结局。这些数据提示需要进一步评估在追求 MVR 方面的最佳策略,包括患者选择、血运重建方式以及评估血运重建完全性的方法。